NCT02092350View on ClinicalTrials.gov

Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

237

Participants

Timeline

Start Date

March 17, 2014

Primary Completion Date

March 11, 2015

Study Completion Date

September 2, 2015

Conditions

Hepatitis C Virus

Interventions

DRUG

Grazoprevir

Grazoprevir 100 mg tablet

DRUG

Elbasvir

Elbasvir 50 mg tablet

DRUG

Placebo to Grazoprevir

Placebo tablet matched to grazoprevir

DRUG

Placebo to Elbasvir

Placebo tablet matched to elbasvir

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02092350 - Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) | Biotech Hunter | Biotech Hunter